Related Experiment Video
Updated: Apr 13, 2026

Computerized Adaptive Testing System of Functional Assessment of Stroke
Published on: January 7, 2019
Identifying high-risk components in online adaptive RT through a multi-centre FMEA to inform clinical trial QA needs
Sarah O Osman1, Alex Dunlop2, Sophie Alexander3
1National Radiotherapy Trials Quality Assurance (RTTQA) Group, Northwood, London, UK; Department of Radiotherapy Physics, University College London Hospital, London, UK.
Background:
Online adaptive radiotherapy (oART) has recently gained traction due to its potential clinical benefits. However, it presents significant challenges in developing effective quality assurance (QA) programs, particularly within multi-centre, multi-platform clinical trials settings. In this study, a Failure Mode and Effects Analysis (FMEA) was conducted to identify high-risk components of oART across different centres using different platforms and workflows to inform the development of risk-based QA processes for multi-centre clinical trials.
Materials And Methods:
The National Radiotherapy Trials Quality Assurance (RTTQA) Group and domain experts from five UK radiotherapy centres using oART conducted an FMEA following AAPM Task Group 100 (TG-100) guidelines. Through collaborative discussions, participants identified a comprehensive list of oART-specific failure modes (FMs) and agreed on scoring guidance for rating their occurrence (O), severity (S), and detectability (D). Finally, this standardised scoring system and guidance were used by multidisciplinary teams from different centres to independently score the FMs and the risk priority numbers were calculated as RPN = O*S*D. Median RPN scores were used to rank the FMs from high to low risk.
Results:
The two FMs representing the greatest risk in the oART workflow were linked to the daily outlining step; incorrect contouring due to missing or inaccurate clinical information RPN (Median [Range]) = 96 [16 - 120], followed by target or OAR delineation errors RPN = 56 [16 - 140]. These failures were mostly associated with insufficient manual review. Overall, contouring, imaging, dose calculation, and plan appraising FMs were rated as highest risk. These FMs were predominantly operator/workflow dependent.
Conclusion:
FMEA identified critical oART-specific FMs requiring targeted QA within clinical trials. Mitigating variability is fundamental to ensuring the validity of clinical trial endpoints. Workflow variability matters: scoring differences across centres highlight the need for harmonisation or cross-validation via end-to-end testing.
More Related Videos
07:31Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Therapeutic Drug Monitoring: Affecting Factors
Bioavailability Study Design: Healthy Subjects Versus Patients
Assumptions of Survival Analysis